

Tables

Table 1 Frequency, percentage, and Mean \pm Standard deviation age of eligible cancer patients for getting influenza vaccine (vaccination from October 1 to 15, 2020)

type	Frequency	Percent	mean	SD	Min	Max
Biliary Tract	7	2.4	54.43	7.5	43	63
Bladder	3	1.0	61	2.000	59	63
Breast	107	37.2	48.34	11.6	27	74
Cervix	2	0.7	46	8.5	40	52
Gastrointestinal	85	29.5	56.28	11.5	26	76
Glioblastoma Multiform	4	1.4	51.25	2.9	49	55
Hematological	29	10.1	51.66	16.5	18	78
Lung	14	4.9	58	7.5	43	66
Melanoma	2	0.7	41	4.2	38	44
Metastasis of unknown origin	2	0.7	55.5	6.4	51	60
Nasopharyngeal Carcinoma	2	0.7	34	2.8	32	36
Osteosarcoma	2	0.7	33	1.4	32	34
Ovarian	6	2.1	49	12.3	35	64
Pancreas	6	2.1	55.33	8.4	48	66
Salivary and Parotid	2	0.7	59	24	42	76
Sarcoma	2	0.7	42	0.0	42	42
Testis and Prostate	4	1.4	58	21.1	29	79
Uterine	3	1.0	54.33	7.0	47	61
Other*	6	2.1	46	11.5	31	66
Total	288	100.0	51.92	12.46	18	79

* Other cancers include: Brain, Desmoids, Hepatocellular, Carcinoma, Peri-ampullary, Squamous Cell Carcinoma, and Thymoma

Table 2 Frequency and percentage of eligible cancer patients for getting influenza vaccine in terms of Covid-19 disease or history of that, comorbidity, and the adverse effect of vaccination based on demographic variables and disease stage in different types of cancer (vaccination from October 1 to 15, 2020)

variable	categorical	Covid-19		Comorbidity		The adverse effect of vaccination		total
		yes	No	yes	No	yes	No	
gender	male	3	109	2	110	1	111	112
		2.7%	97.3%	1.8%	98.2%	0.9%	99.1%	
gender	female	2	174	2	174	1	175	176
		1.1%	98.9%	1.1%	98.9%	0.6%	99.4%	
Age group	< 40	1	48	1	48	0	49	49
		2.0%	98.0%	2.0%	98.0%	0.0%	100.0%	
	40 - 59	3	150	2	151	2	151	153
		2.0%	98.0%	1.3%	98.7%	1.3%	98.7%	
≥ 60	1	85	1	85	0	86	86	
	1.2%	98.8%	1.2%	98.8%	0.0%	100.0%		
Stage	II	0	51	0	51	0	51	51
		0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
	III	1	77	2	76	0	78	78
		1.3%	98.7%	2.6%	97.4%	0.0%	100.0%	
	IV	2	86	1	87	2	86	88
		2.3%	97.7%	1.1%	98.9%	2.3%	97.7%	
Relapsed	0	33	0	33	0	33	33	
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%		
unknown	2	36	1	37	0	38	38	
	5.3%	94.7%	2.6%	97.4%	0.0%	100.0%		
Rituximab	yes	0	5	0	5	0	5	5
		0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Rituximab	no	5	278	4	279	2	281	283
		1.8%	98.2%	1.4%	98.6%	0.7%	99.3%	
Total		5*	283	4**	284	2***	287	288

Table 3 Frequency and percentage of eligible cancer patients for getting influenza vaccine in terms of Covid-19 disease or history of that, comorbidity, and the adverse effect of vaccination based on cancer types (vaccination from October 1 to 15, 2020)

Type	Covid-19		Comorbidity		The adverse effect of vaccination		total
	yes	No	yes	No	yes	No	
Biliary Tract	1	6	0	7	0	7	7
	14.3%	85.7%	0.0%	100.0%	0.0%	100.0%	
Bladder	0	3	0	3	0	3	3
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Breast	0	107	1	106	1	106	107
	0.0%	100.0%	0.9%	99.1%	0.9%	99.1%	
Cervix	0	2	1	1	0	2	2
	0.0%	100.0%	50.0%	50.0%	0.0%	100.0%	
Gastrointestinal	3	82	1	84	1	84	85
	3.5%	96.5%	1.2%	98.8%	1.2%	98.8%	
Glioblastoma Multiform	0	4	0	4	0	4	4
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Hematological	1	28	0	29	0	29	29
	3.4%	96.6%	0.0%	100.0%	0.0%	100.0%	
Lung	0	14	0	14	0	14	14
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Melanoma	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Metastasis of unknown origin	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Nasopharyngeal Carcinoma	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Osteosarcoma	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Ovarian	0	6	0	6	0	6	6
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Pancreas	0	6	0	6	0	6	6
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Salivary and Parotid	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Sarcoma	0	2	0	2	0	2	2
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	

Testis and Prostate	0	4	0	4	0	4	4
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Uterine	0	3	0	3	0	3	3
	0.0%	100.0%	0.0%	100.0%	0.0%	100.0%	
Other	0	6	1	5	0	6	6
	0.0%	100.0%	16.7%	83.3%	0.0%	100.0%	
Total	5	283	4	284	2	286	288

